

The majority of male patients with COVID-19 present low testosterone levels on admission to Intensive Care in Hamburg, Germany: a retrospective cohort study.

Maria Schroeder (MD)^{1,*}, BerfinTuku² (MSc)*, Dominik Jarczak (MD)¹, Axel Nierhaus (MD)¹, Tian Bai (MSc)², Henning Jacobsen (MSc)², Martin Zickler (MSc)², Zacharias Müller (BSc)², Stephanie Stanelle-Bertram (PhD)², Andreas Meinhardt (PhD)⁴, Jens Aberle (MD)⁵, Stefan Kluge (MD)^{1,§}, Gülsah Gabriel (PhD)^{2,3,§}

¹Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Department for Viral Zoonoses-One Health, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany; ³Institute for Virology, University for Veterinary Medicine Hannover, Hannover, Germany; ⁴Institute of Anatomy and Cell Biology, Justus-Liebig University of Giessen, Germany; ⁵Department of Endocrinology, Diabetology, Obesity and Lipids, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

*shared first authorship; §shared last authorship

correspondance to: guelsah.gabriel@leibniz-hpi.de

Figure S1

Cytokines and chemokine levels in COVID-19 male and female patients

Cytokine and chemokine levels were measured in the sera/plasma from Covid-19 infected male and female patients. Statistical significance was assessed by Student's *t*-test (* $p < 0.05$).




Figure S1